Alcon Signs Agreement With AstraZeneca On Eye Drug Development
Published: 22-Jul-2009
Alcon and AstraZeneca are targeting development of drugs to treat sight-threatening diseases
Alcon has entered into a five-year collaborative research agreement with AstraZeneca, for the exclusive ophthalmic discovery and potential development rights to AstraZeneca’s compound library.
Reportedly, the two companies are targeting development of drugs to treat sight-threatening conditions such as glaucoma, wet and dry age-related macular degeneration and other retinal diseases, as well as ocular allergy, dry eye and other inflammatory eye conditions.
Under the terms of the agreement, Alcon obtains immediate access to thousands of AstraZeneca compounds in a variety of drug classes. AstraZeneca will hand over development and regulatory documentation associated with each compound as relevant to ophthalmology.
Additionally, Alcon will perform and fund all research and development activities to move selected compounds forward.
In addition, the agreement provides for individual license agreements to be negotiated on a case by case basis for any compound that moves into clinical development, including regulatory milestone payments and royalties on product sales.
Sabri Markabi, senior vice president of research and development and chief medical officer of Alcon, said: “Our agreement with AstraZeneca stems from our strategy of enhanced access to sources of technologies and compounds through partnership with leading biomedical research organizations. The combination of AstraZeneca’s broad capabilities in discovery and Alcon’s scientific expertise in eye disease provides potential for therapies that fulfil unmet medical needs in ophthalmology.”
Network Sites

Suppliers To This Sector
Browse A-Z
Solutions4Science
Temperature Mapping and Validation Services ...
Exploristics
Innovative Analysis Solutions for Data Exploration, Pharmacogenetics, Biomarkers and Exploratory Sta...
NeuroProof
Screening Services for Pre-Clinical Development of Neuro-Pharmaceuticals and Safety Pharmacology ...
DASGIP
Parallel Bioreactor Systems for the Cultivation of Bacterial, Phototrophic, Animal and Human Cells ...
BioKinetic Europe
Phase I/II Contract Research Organisation ...
Toxikon Europe
CRO Providing Preclinical Safety Studies for the Life Science Community ...
White Papers
Browse A-Z
GRACO's New FDA Pumps
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
GRACO's New Hydra-Clean
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
GRACO's New 1590 & 3150 Pumps
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
Customer Testimonial – Astra Zeneca
From the control room to the downstream processing area and with an eye on utilities servi ...
Hygienic Processing
From the control room to the downstream processing area and with an eye on utilities servi ...


Delicious
Digg
Reddit
Stumble
LinkedIn
Mail sent successfully